

UBMTA Implementing Letter

Note: this letter contains additional binding terms at page 2

**For the complete terms of the UBMTA please see:
<http://www.autm.net/ubmta/UBMTAWord.doc>**

Massachusetts General Hospital **UBMTA Implementing Letter**

The purpose of this letter is to provide a record of the biological material transfer, to memorialize the agreement between the PROVIDER SCIENTIST (identified below) and the RECIPIENT SCIENTIST (identified below) to abide by all terms and conditions of the Uniform Biological Material Transfer Agreement ("UBMTA") March 8, 1995, and to certify that the RECIPIENT (identified below) organization has accepted and signed an unmodified copy of the UBMTA. The RECIPIENT organization's Authorized Official also will sign this letter if the RECIPIENT SCIENTIST is not authorized to certify on behalf of the RECIPIENT organization. The RECIPIENT SCIENTIST (and the Authorized Official of RECIPIENT, if necessary) should sign both copies of this letter and return one signed copy to the PROVIDER. The PROVIDER SCIENTIST will forward the material to the RECIPIENT SCIENTIST upon receipt of the signed copy from the RECIPIENT organization.

Please fill in all of the blank lines below:

1. PROVIDER: Organization providing the ORIGINAL MATERIAL:

Organization: The General Hospital Corp. d/b/a/ Massachusetts General Hospital

Address: 55 Fruit Street
Boston, MA 02114

2. RECIPIENT: Organization receiving the ORIGINAL MATERIAL:

Organization: _____
Address: _____

3. ORIGINAL MATERIAL (Enter description):

Heterozygous immune compromised zebrafish will be provided as embryos and contain inactivating and/or hypomorphic mutations within recombination-activating gene (rag2), DNA-dependent protein kinase catalytic subunit (prkdc), janus kinase 3 (jak3), interleukin-2 receptor gamma orthologues (il2rga and/or il2rgb), zap70 and forkhead box n1 (fonx1). Description of these lines is provided in NIH grant R24OD016761 with mutant lines corresponding to ZFIN allele designations fb101-fb120.

4. Termination date for this letter (optional): N/A

5. Transmittal Fee to reimburse the PROVIDER for preparation and distribution costs (optional).
Amount: \$__0_(if shipped prior to August 2017).

Additional Binding Terms:

In the event of any conflict between the terms of the UBMTA and any additional binding terms set forth herein, such additional binding terms shall govern.

- RECIPIENT shall not use the ORIGINAL MATERIAL or MODIFICATIONS in any research that is subject to consulting or licensing obligations to any third party, with the exception of U.S. government funded research.
- RECIPIENT may only transfer MODIFICATIONS to NONPROFIT ORGANIZATIONS under a material transfer agreement no less restrictive than the terms than the terms of this agreement (including the Additional Binding Terms herein).
- RECIPIENT represents that it is a NONPROFIT ORGANIZATION as defined in the UBMTA.
- RECIPIENT SCIENTIST shall cite the source of the Original Material and acknowledge the grant to which the ORIGINAL MATERIAL was created: R24OD016761.
- RECIPIENT SCIENTIST must submit a request to Dr. David Langenau for each specific allele/mutant of the ORIGINAL MATERIAL ("Zebrafish Line"). PROVIDER is under no obligation to provide all or any of the requested Zebrafish Line(s) as same may not be currently available. PROVIDER shall honor such request to the extent that the requested Zebrafish Line is available.
- Neither party shall use the name, trademark, service mark, logo or other identifying characteristic ("Name") of the other party or any of its affiliates, or any of its or their respective directors, trustees, officers, appointees, employees, staff, representatives or agents, in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the party or individual whose Name is to be used. In the case of PROVIDER, such approval shall be given solely by its Department of Public Affairs.

This Implementing Letter is effective when signed by all parties. The parties executing this Implementing Letter certify that their respective organizations have either: (i) accepted and are signatories to the UBMTA, or (ii) agrees to be bound by the terms of the UBMTA. RECIPIENT further agrees to be bound by the Additional Binding Terms above, for the transfer specified herein.

RECIPIENT SCIENTIST certifies having read and understood the entire agreement:

Name: _____

Title: _____

Address: _____

Signature: _____

Date: _____

RECIPIENT ORGANIZATION CERTIFICATION

Authorized Official: _____

Title: _____

Address: _____

Signature: _____

Date: _____

PROVIDER ORGANIZATION CERTIFICATION

Authorized Official: _____
Title: _____
Address: 399 Revolution Drive, Suite 755
Somerville, MA 02145
Signature: _____
Date: _____

PLEASE SUBMIT THIS AGREEMENT FOR REVIEW AND APPROVAL BY THE APPROPRIATE OFFICE AT YOUR INSTITUTION. IF ACCEPTABLE, PLEASE SIGN THE AGREEMENT AND **FORWARD A PDF SIGNATURE COPY VIA EMAIL (NO ORIGINALS ARE NECESSARY)** TO:

ABICA-HUIU@PARTNERS.ORG

Alina Bica-Huiu, JD
Partners Innovation
399 Revolution Drive, Suite 755
Somerville, MA 02145
857-282-1803